Often, the factors that derail future expansions are the ones nobody’s talking about. These five overlooked details can make a facility more flexible — or more fragile than expected.
Dennis Group engineers and project managers discuss the lesser-known factors that can make or break a food manufacturing plant’s long-term expandability.
Some new ERP providers are building their systems from scratch totally on AI, but can their systems fulfill all the demands that manufacturers have expected from conventional ERP over the years?
As food manufacturers approach a turning point in the application, verification and sharing of product data, a practical roadmap can support faster implementation, stronger compliance outcomes and measurable operational efficiencies.
Dairy processors are racing to add capacity as whey protein demand outruns supply. The harder question is whether that capacity can come online when it's needed.
Older facilities, in many cases, can be maintained to protect ingredients and finished goods. However, attention should be paid to drainage systems, along with monitoring environmental temperatures, humidity and airflows in critical spaces.
With disciplined planning and support from local business programs, Rebecca and Will Brady have doubled the production capacity of their seed-based cracker company.
Rebecca Brady, CEO of Top Seedz, and her husband Will Brady, COO, are expanding and automating operations, recently commissioning a second manufacturing line. This has doubled production capacity, putting Top Seedz on track to reach $100 million in annual sales.
EIC Alyse Thompson-Richards reports on recent food and beverage industry developments, including new plants from Bauducco and Gelatys, expansions from Killer Brownie and DG Foods, and Good Culture’s partnership with a Michigan dairy co-op.
This work will inform the agency’s upcoming post-market safety assessment of the food contact uses of phthalates.
The U.S. FDA has evaluated eight ortho-(o)-phthalates used as plasticizers in food contact for a cumulative risk assessment. This analysis will inform the FDA's upcoming safety assessment and determine if these substances should be grouped based on their chemical or pharmacological similarities.